Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1693-1706

  Shevde, Lalita A ^a   Metge, Brandon J ^a   Mitra, Aparna ^a   Xi, Yaguang ^a   Ju, Jingfang ^a   King, Judy A ^b   Samant, Rajeev S ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Breast cancer; Hsa mir 299 5p; MiRNA; Osteopontin; Vasculogenic mimicry

Indexed keywords

MICRORNA; MIRN299 MICRORNA, HUMAN; OSTEOPONTIN;

ARTICLE; BREAST TUMOR; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECRETION; TUMOR CELL CULTURE; ULTRASTRUCTURE; VASCULARIZATION;

BREAST NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 77955146050     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00821.x     Document Type: Article

References (81)

1. Li X, Lewis MT, Huang J. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008, 100:672-9.
2. McGrogan BT, Gilmartin B, Carney DN. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008, 1785:96-132.
3. Campone M, Campion L, Roche H. Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat. 2008, 109:491-501.
4. Kim JB, Stein R, O'Hare MJ. Three-dimensional in vitro tissue culture models of breast cancer- a review. Breast Cancer Res Treat. 2004, 85:281-91.
5. Mayer B, Klement G, Kaneko M. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology. 2001, 121:839-52.
6. Ivascu A, Kubbies M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol. 2007, 31:1403-13.
7. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene. 2009, 28:461-8.
8. Laderoute KR, Murphy BJ, Short SM. Enhancement of transforming growth factor-alpha synthesis in multicellular tumour spheroids of A431 squamous carcinoma cells. Br J Cancer. 1992, 65:157-62.
9. Theodorescu D, Sheehan C, Kerbel RS. TGF-beta gene expression depends on tissue architecture. In Vitro Cell Dev Biol. 1993, 29A:105-8.
10. Kerbel RS, Rak J, Kobayashi H. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb Symp Quant Biol. 1994, 59:661-72.
11. Kobayashi H, Man S, Graham CH. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A. 1993, 90:3294-8.
12. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 2008, 7:3655-60.
13. Takamizawa J, Konishi H, Yanagisawa K. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-6.
14. Wu W, Sun M, Zou GM. MicroRNA and cancer: Current status and prospective. Int J Cancer. 2007, 120:953-60.
15. Jay C, Nemunaitis J, Chen P. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007, 26:293-300.
16. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007, 20:425-37.
17. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007, 6:60.
18. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008, 10:203.
19. Lowery AJ, Miller N, McNeill RE. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res. 2008, 14:360-5.
20. Zhang B, Pan X, Cobb GP. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007, 302:1-12.
21. Iorio MV, Ferracin M, Liu CG. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-70.
22. Gregory PA, Bert AG, Paterson EL. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008, 10:593-601.
23. Tavazoie SF, Alarcon C, Oskarsson T. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008, 451:147-52.
24. Huang Q, Gumireddy K, Schrier M. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008, 10:202-10.
25. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007, 449:682-8.
26. Zhao JJ, Lin J, Yang H. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008, 283:31079-86.
27. Miller TE, Ghoshal K, Ramaswamy B. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008, 283:29897-903.
28. Kovalchuk O, Filkowski J, Meservy J. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008, 7:2152-9.
29. Shevde LA, Samant RS, Paik JC. Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435. Clin Exp Metastasis. 2006, 23:123-33.
30. Rodrigues LR, Teixeira JA, Schmitt FL. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16:1087-97.
31. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006, 25:2192-202.
32. Shevde LA, Samant RS, Goldberg SF. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res. 2002, 273:229-39.
33. Standal T, Hjorth-Hansen H, Rasmussen T. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica. 2004, 89:174-82.
34. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol. 2004, 26:179-84.
35. Bramwell VH, Doig GS, Tuck AB. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006, 12:3337-43.
36. Chambers AF, Wilson SM, Kerkvliet N. Osteopontin expression in lung cancer. Lung Cancer. 1996, 15:311-23.
37. Fedarko NS, Jain A, Karadag A. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001, 7:4060-6.
38. Kim YW, Park YK, Lee J. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci. 1998, 13:652-7.
39. Rudland PS, Platt-Higgins A, El-Tanani M. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002, 62:3417-27.
40. Singhal H, Bautista DS, Tonkin KS. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res. 1997, 3:605-11.
41. Tuck AB, O'Malley FP, Singhal H. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer. 1998, 79:502-8.
42. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68:152-61.
43. Chakraborty G, Jain S, Behera R. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006, 6:819-30.
44. Hamada Y, Yuki K, Okazaki M. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Dent Mater J. 2004, 23:650-5.
45. Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res. 2006, 66:6638-48.
46. Santner SJ, Dawson PJ, Tait L. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 2001, 65:101-10.
47. Miller FR, Santner SJ, Tait L. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000, 92:1185-6.
48. Strickland LB, Dawson PJ, Santner SJ. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat. 2000, 64:235-40.
49. Dontu G, Abdallah WM, Foley JM. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-70.
50. http://microrna.sanger.ac.uk/targets/
51. Golden T, Aragon IV, Rutland B. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim Biophys Acta. 2008, 1782:259-70.
52. Al-Hajj M, Wicha MS, Benito-Hernandez A. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003, 100:3983-8.
53. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004, 23:7274-82.
54. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol. 1995, 146:95-100.
55. Furger KA, Menon RK, Tuck AB. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001, 1:621-32.
56. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003, 278:14487-97.
57. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001, 276:44926-35.
58. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000, 156:361-81.
59. Robert A FJ. Nanomedicine Vol. I: Basic capabilities 1999, Volume I. Georgetown, TX, Landes Bioscience
60. Hendrix MJ, Seftor EA, Kirschmann DA. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res. 2000, 2:417-22.
61. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988, 240:177-84.
62. Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia. 2004, 9:297-310.
63. Desoize B, Gimonet D, Jardiller JC. Cell culture as spheroids: an approach to multicellular resistance. Anticancer Res. 1998, 18:4147-58.
64. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006, 6:583-92.
65. Kunz-Schughart LA, Freyer JP, Hofstaedter F. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen. 2004, 9:273-85.
66. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006, 66:4553-7.
67. Ponti D, Zaffaroni N, Capelli C. Breast cancer stem cells: an overview. Eur J Cancer. 2006, 42:1219-24.
68. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell. 2007, 11:3-5.
69. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001, 6:419-29.
70. Chellaiah MA, Hruska KA. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int. 2003, 72:197-205.
71. Khan SA, Cook AC, Kappil M. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis. 2005, 22:663-73.
72. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007, 117:3155-63.
73. Polyak K. Is breast tumor progression really linear. Clin Cancer Res. 2008, 14:339-41.
74. Folkman J. Angiogenesis. Annu Rev Med. 2006, 57:1-18.
75. Khan SA, Lopez-Chua CA, Zhang J. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem. 2002, 85:728-36.
76. Hirama M, Takahashi F, Takahashi K. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003, 198:107-17.
77. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett. 2005, 218:1-14.
78. Rak J. Is cancer stem cell a cell, or a multicellular unit capable of inducing angiogenesis. Med Hypotheses. 2006, 66:601-4.
79. Liu W, Mao SY, Zhu WY. Impact of tiny miRNAs on cancers. World J Gastroenterol. 2007, 13:497-502.
80. Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development. 2007, 134:1635-41.
81. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001, 107:823-6.